Kanttekening bij coronaire plaquefenotypeveranderingen onder lipidenverlagende therapie

We read with great interest the systematic review and meta-regression by Patti et al., which examines the relationship between lipid-lowering therapy (LLT)-induced changes in coronary plaque phenotype and major adverse cardiovascular events (MACE) [1]. The authors deserve recognition for this innovative analysis that attempts to quantify a biologically plausible yet elusive link. Their central finding - that each 10° decrease in maximum lipid arc measured by optical coherence tomography (OCT) correlates with a 39 % reduction in MACE risk - is compelling [1].